News tagged with tamoxifen
Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer
A new analysis has provided a comprehensive comparison of scores designed to predict which women with oestrogen-receptor positive breast cancer are at high risk of recurrence beyond five years after diagnosis, and may benefit ...
Cancer
May 02, 2013 |
not rated yet |
0
Coffee may help prevent breast cancer returning, study finds
Drinking coffee could decrease the risk of breast cancer recurring in patients taking the widely used drug Tamoxifen, a study at Lund University in Sweden has found. Patients who took the pill, along with ...
Cancer
Apr 25, 2013 |
4 / 5 (1) |
0
Researchers identify new pathway, enhancing tamoxifen to tame aggressive breast cancer
Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen's secondary ...
Cancer
Apr 23, 2013 |
5 / 5 (1) |
0
Mammograms reveal response to common cancer drug
Researchers at Karolinska Institutet have developed a method for assessing the effect of tamoxifen, a common drug to prevent the relapse of breast cancer. The key lies in monitoring changes in the proportion of dense tissue, ...
Cancer
Apr 22, 2013 |
not rated yet |
0
Cold winters freezing out breast cancer treatment
For women diagnosed with a form of breast cancer known as estrogen receptor positive (ER+) breast cancer, tamoxifen is an essential drug used in the treatment and prevention of recurring breast cancer. Currently, tamoxifen ...
Cancer
Apr 18, 2013 |
not rated yet |
0
Drugs can cut breast cancer risk for some, task force finds
(HealthDay)—The drugs tamoxifen and raloxifene (Evista) could reduce the risk of breast cancer among women who are at high risk of developing the disease, a new report confirms.
Cancer
Apr 16, 2013 |
not rated yet |
0
Excess estrogen in pregnancy can silence BRCA1 in daughters, increasing breast cancer risk
Excess estrogen levels during pregnancy can disable, in their daughters, a powerful breast cancer tumor suppressor gene, say researchers at Georgetown Lombardi Comprehensive Cancer Center. They found the DNA repair gene BRCA1 ...
Cancer
Apr 09, 2013 |
not rated yet |
0
25 percent don't complete recommended breast cancer treatment
One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course, according to a new study led by University of Michigan ...
Cancer
Apr 09, 2013 |
not rated yet |
0
UK considers preventative drugs for breast cancer (Update)
Britain's National Health Service may soon offer women at high risk of developing breast cancer drugs normally used to treat the disease as a prevention strategy.
Cancer
Jan 15, 2013 |
not rated yet |
0
Tamoxifen ameliorates symptoms of Duchenne muscular dystrophy
A new study has found that tamoxifen, a well-known breast cancer drug, can counteract some pathologic features in a mouse model of Duchenne muscular dystrophy (DMD). At present, no treatment is known to produce ...
Diseases, Conditions, Syndromes
Jan 15, 2013 |
3 / 5 (1) |
0
|
Ability to metabolize tamoxifen affects breast cancer outcomes, study confirms
For nearly a decade, breast cancer researchers studying the hormone therapy tamoxifen have been divided as to whether genetic differences in a liver enzyme affect the drug's effectiveness and the likelihood breast cancer ...
Cancer
Dec 27, 2012 |
not rated yet |
0
|
Tamoxifen trial should prompt breast cancer patients to reconsider treatment options
A groundbreaking clinical trial involving the breast cancer drug tamoxifen should prompt certain breast cancer patients to reconsider their treatment options, according to Loyola University Medical Center breast cancer specialist ...
Cancer
Dec 06, 2012 |
not rated yet |
0
10 years of tamoxifen better than 5, study reports
(HealthDay) —Taking the breast cancer drug tamoxifen for a decade, instead of the standard five years, further reduces the long-term chances of recurrence and risk of dying from the disease, new British ...
Cancer
Dec 05, 2012 |
not rated yet |
0
SABCS: Extending tamoxifen to 10 years beneficial in breast CA
(HealthDay)—For women with estrogen receptor (ER)-positive early breast cancer, continuing tamoxifen to 10 years correlates with reduced risk of recurrence and lower breast cancer-specific and overall mortality, ...
Cancer
Dec 05, 2012 |
not rated yet |
0
Hedgehog pathway key in tamoxifen-resistant breast CA
(HealthDay)—Noncanonical Hedgehog (Hh) signaling is activated in tamoxifen-resistant tumors, and the phosphoinositide 3-kinase inhibitor/protein kinase B (PI3K/AKT) pathway plays a key role protecting Hh ...
Cancer
Nov 06, 2012 |
not rated yet |
0
Tamoxifen
Tamoxifen is an antagonist of the estrogen receptor in breast tissue and is therefore used in the treatment of breast cancer. As of 2004, it was the world's largest selling drug for that purpose.
Some breast cancer cells require estrogen to grow. Estrogen binds to and activates the estrogen receptor in these cells. Tamoxifen is metabolized into compounds that also bind to the estrogen receptor but do not activate it. Furthermore tamoxifen prevents estrogen from binding to its receptor. Hence breast cancer cell growth is blocked.
Tamoxifen was discovered by ICI Pharmaceuticals (now AstraZeneca) and is sold under the trade names Nolvadex, Istubal, and Valodex. However, the drug, even before its patent expiration, was and still is widely referred to by its generic name "tamoxifen."
For more information about Tamoxifen, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
